British American Tobacco p.l.c. (BATS) Earnings Call Transcript & Summary
July 25, 2024
Earnings Call Speaker Segments
Tadeu Marroco
executiveGood morning, everyone. It’s a pleasure to welcome all of you to the presentation of our 2024 interim results. Joining me this morning are Soraya Benchikh, our new CFO, and Victoria Buxton, Group Head of Investor Relations. I’ll start by covering the highlights of our transformation and the progress achieved in our key focus areas over the last 12 months. After that, Soraya will walk you through our financial performance in greater detail. Then I’ll come back to discuss more about the outlook for our performance before we open the Q&A session. With that, please direct your attention to the disclaimers on slides two and three. So let’s start by examining the way forward. Our first half performance matches expectations, and we remain on track to deliver our full year guidance. During the first half of this year, we kept transforming our business. We added 1.4 million smokeless consumers, bringing the total to 26.4 million. Smokeless now represents 18% of group revenue, an increase of 1.4 percentage points compared with full year 2023. Our emphasis on quality growth, balancing delivery on both the top and bottom lines, has produced a GBP 165 million rise in New Category contribution and an increase of close to 10 percentage points in our category contribution margin.
Tadeu Marroco
executiveWith that momentum behind us, we're anticipating yet another solid rise in New Category contribution across the full year. Rewarding shareholders through robust cash returns remains our commitment, and I'm happy with how we've progressed on boosting financial flexibility — which has made it possible to begin a sustainable share buyback. This year stands as a pivotal point in our transformation journey, as we hone our execution, which lets us steer through near-term market challenges and propel our sustainable transformation. Now to the drivers behind 2024 delivery. Just as we guided previously, 2024 is an investment year for BAT. During the first half, we've put investment into strengthening our U.S. business, speeding up innovation momentum, and improving capabilities that underpin our strategic delivery. That factor, combined with lapping a tough comparator in APMEA, means we anticipate an acceleration in our second half performance. It encourages me that our New Category launchings and our first half U.S. investments are building traction. Along with the expected unwind of U.S. wholesale inventory movements tied to the year-on-year timing of our first half price increase, I'm confident we're on track to deliver our full year guidance. At this point last year, I laid out a clear set of objectives aimed at honing our execution and building a more modern and agile BAT.
Tadeu Marroco
executiveAcross the past 12 months, in partnership with our wider teams, we've achieved solid progress on these 6 priority areas. As we move through today's presentation, we'll cover a few of those highlights more closely. There remains more work ahead, but progress is coming along well, and I have confidence that the decisions we've taken and the steps we're implementing represent the correct path ahead for BAT. With that said, I'll pass things to Soraya, who will walk you through the specifics of our results.
Soraya Benchikh
executiveThanks, Tadeu, and good morning to all of you. I'm Soraya Benchikh, the CFO of BAT, and ahead of walking you through the results, let me introduce myself. I'm Lebanese, and after beginning my finance career at Gillette and GE, I went on to work for many years at BAT in Europe, Russia, Africa, and the Middle East. The past 12 years have been spent in general management, with my last 4 at Diageo, where I ultimately served as President for Europe. Now, having been back at BAT for 2 months, I'm thrilled to be joining Tadeu and the team to work on the next stage of our transformation. In my role as CFO, I'll focus on supporting BAT's transformation through financial stability and effective resource allocation. That means driving quality growth by balancing top and bottom line performance and targeting investments so they deliver better returns and consistent cash generation. I'll do this by prioritizing an understanding of market trends and consumer needs, investing in innovation and R&D, streamlining operations for efficiencies, while managing organizational change effectively and aligning with our sustainability goals. Transformative leadership is something I'm passionate about, and I'm committed to fostering creative, inclusive, and empowered teams. Keeping communication with stakeholders transparent and consistent also matters greatly to me, and I very much look forward to sharing insights into our performance and future outlook with you.
Soraya Benchikh
executiveTurning now to the results for our first half. The figures we reported show the effect of leaving Russia and Belarus in September of last year, along with larger amortization and impairment charges that followed our decision to begin amortizing the U.S. acquired combustible brands starting January 2024, and once more, charges recognized in connection with the partial sale of the group's investment in ITC. So that the underlying performance of the business is easier to understand and to give a like-for-like comparison that leaves out Russia and Belarus, our focus today will be on organic, adjusted, constant currency results, except where we say otherwise. Group revenue declined 0.8%, although New Category revenue rose more than 7%. Profit from operations fell 0.9%, and diluted EPS increased 1.3%. Although continued macroeconomic headwinds in the U.S. have weighed on our group results, we have also made targeted investment choices, including: continued investment in our U.S. commercial plans together with related wholesaler inventory movements, and investment in New Category launches around the world so as to strengthen our portfolio and drive sustainable growth and value creation. As you can see, the wholesaler inventory movements in the U.S. had a significant impact on our first half delivery. Without them, group revenue would have been flat and profit from operations would have risen 0.5%.
Soraya Benchikh
executiveWe anticipate those movements reversing in the second half, and they should not meaningfully affect our full-year delivery. Now, let's get into a few of the main drivers behind our performance. Combustibles price mix came in at 4.3%, with pricing rising 7.2%, offset by a negative geographic mix, largely due to the U.S.. Beyond that, operating margin was flat, thanks to gains in our New Category contribution and our ongoing efficiency efforts, even while we absorbed a 1.8% transactional effects headwind. Leaving aside the U.S., which I'll cover in greater detail shortly, across the rest of the world we posted 4% revenue growth and 4.6% growth in profit from operations, consistent with our medium-term guidance. That speaks to the resilience of our multi-category portfolio and the advantages of our global footprint. New Category revenue growth during the first half was powered by a standout performance from Velo across all three regions. We anticipate New Category performance speeding up in the second half, driven by how our innovation launches are phased, something we'll address in more detail later in the presentation. Let me now give you more detail on the main category drivers. As always, market shares for our top markets can be found in the appendix.
Soraya Benchikh
executiveTurning to vapor, the fundamentals in that category look very strong. The overall count of vapor users keeps rising, and vapor accounts for the biggest piece of active New Category usage, drawing in 65% of consumers. Vuse revenue rose almost 3%, and the brand kept delivering a positive contribution to the category. We saw solid revenue growth in Europe and APMEA, partly offset by the effect of illicit single-use vapor products in the U.S. and Canada. Vuse held on to global value share leadership and stays the number one brand in the U.S. as well. Although we are losing share in the U.S. because illicit products keep spreading, we are working hard to push for more effective regulation and enforcement at both the state and federal levels. In June, we filed the age-gated Vuse Pro PMTA, and last week we obtained a marketing granted order for our Vuse Alto device and tobacco flavors, which confirms that continuing to market these products is appropriate for the protection of public health. Beyond the U.S., we kept value share leadership in AME at 32%. Now, even though our regional performance took a hit from the flavor ban in Quebec province in Canada, where volume has moved into the illegal market because of weak enforcement, our value share in Europe climbed 120 basis points.
Soraya Benchikh
executiveWe're genuinely enthusiastic about the opportunity taking shape in APMEA, where our revenue has climbed 48%, powered by South Korea, New Zealand, and Indonesia. Within heated products, industry expansion is decelerating as poly usage rises. Glo's revenue fell 4%, largely reflecting price repositioning in Japan and Italy during mid-2023, along with Velo pipeline build at the close of 2023 in certain AME markets, ahead of the flavor ban on tobacco consumables. Since December, Glo has begun posting sequential gains in category volume share across key markets, and share is now stabilizing—down 20 basis points year to date at 16.8, compared with 110 basis points in 2023. The driver has been the encouraging early consumer response to our new innovations, Hyper Pro and improved consumables. As part of our innovation, Hyper Pro, of our innovation pipeline, Hyper Pro represents an important first step into the premium HP segment. Consequently, we're seeing better performance, with our June volume share up 60 basis points in Japan and up 70 basis points in Italy versus December. That's especially encouraging given that we also raised consumables pricing in both markets during the period. All told, we achieved a strong improvement in total category contribution.
Soraya Benchikh
executiveWith most Hyper Pro launches now finished and Velo, our tobacco-free consumables line, available in 19 markets and beating rival products, we anticipate our second half results will speed up. Now turning to Modern Oral, the New Category expanding quickest, where new markets lacking any oral tradition represent one quarter of industry volume. During H1, revenue climbed 49%, with gains in every region and a rising category contribution. Our market share kept expanding, as our volume share of Modern Oral rose 30 basis points. In AME, we held unmistakable leadership of the Modern Oral category, with 65% volume share, and Velo took the majority of category growth. Velo's ongoing success stems from posting the top consumer acquisition and conversion scores and the strongest brand power in key markets. Importantly, in AME, Velo's gross margin per mil is. In AME, Velo's gross margin per mil exceeds that of combustibles by more than two times, fueling a substantial rise in category contribution. In the U.S., our New York pilot, which features a refreshed Velo brand expression, has produced encouraging results. During H1, we launched nationally, bringing U.S. performance back to strong growth, with revenue up 120% and hitting 7.6% of volume share in June, a rise of 3 percentage points versus December.
Soraya Benchikh
executiveAlso, after favorable results in consumer testing, we launched Grizzly Modern Oral across the U.S. nationally in June. A major priority of mine is making sure that, as we transform, we keep both top-line and bottom-line performance in balance. You can see this in how our New Category contribution is now pushing our contribution margin higher, even as we keep investing for future growth. New categories now add meaningfully to group results, and we're gaining from greater scale and efficiencies. With that momentum behind us, we anticipate a strong year-on-year gain in New Category profitability for 2024. Now to combustibles. On an organic basis, volumes fell 6.9%. The causes were wholesaler inventory movements in the U.S., market exits in 2023, and supply chain disruptions in Sudan. Leaving out those one-offs, our volume declined 4.7%. Volume share rose 30 basis points, helped by strong momentum in key combustible markets including Brazil, Bangladesh, and Pakistan. Value share fell 10 basis points, as the effect of our U.S. commercial actions in the U.S. more than outweighed value share gains in AME and APMEA, which together rose 20 basis points. Revenue declined 2.6%, pulled down by the U.S. and partly offset by resilient performance in AME and APMEA, which together delivered revenue growth of 2.2%.
Soraya Benchikh
executiveMoving on to the regional picture. In the U.S., total revenue fell 7%, largely because of how our combustibles performed and because illicit products are affecting the vapor category. As we mentioned before, we've kept investing actively to strengthen our portfolio, and most of the investment in commercial initiatives that we announced earlier is now finished in the first half. Tadeu will go into more detail on that later in the presentation. Adjusted profit from operations dropped 5%, which came from lower revenue, partly offset by efficiency gains, and that let us widen margins by 100 basis points. When we adjust for wholesaler inventory movements, revenue declined by less than 5%, and adjusted profit from operations declined by 2.6%. U.S. combustibles industry volume was down 10%, or 9.5% on a sales to retail basis, excluding inventory movements. Aside from the secular market decline, industry volume was mostly affected by a mix of macroeconomic headwinds and rising poly usage, particularly because of growth in illicit single-use vapes. Our combustibles volume dropped by 13.7%, ahead of the industry decline, mainly because of wholesaler inventory movements. Excluding the deep discount segment, where we don't compete, the industry decline was nearly 11%, which lines up with our volume decline of 11.4% once adjusted for inventory movements.
Soraya Benchikh
executiveWhile our volume share has fallen 10 basis points year to date and value share has dropped 30 basis points, I'm encouraged that our commercial plans are showing signs of recovery in both volume and value share. Since the last half year, our volume share has risen 10 basis points, driven by a 90 basis point gain in the premium segment. On top of that, we've begun to win back value share, with the decline now at 20 basis points since last half year, led by a 20 basis point rise in our premium share, which has reached its highest level in four years. Thanks to this progress and adjusting for inventory moves, our combustibles contribution has rebounded compared with the last half year. Turning now to outside the U.S., AME is genuinely a multi-category region. Smokeless products account for 25% of regional revenues in the markets where we operate, and more than 50% of revenue in 11 markets. That powered continued strong regional delivery. Revenues were up 5%, fueled by higher combustibles revenue reflecting resilient volume performance and pricing, together with ongoing New Category revenue growth, powered by an excellent Modern Oral performance that rose 47%. Outside Canada, vapor revenues in AME climbed 15%. Adjusted profit from operations rose 5%, as we kept offsetting the impact of inflation through continued efficiency gains.
Soraya Benchikh
executiveIn APMEA, performance held up well against a very strong comparator from the prior year. Total revenue rose 2%, and combustibles revenue increased 1%, supported by solid pricing and partly offset by the industry decline in Australia as well as supply chain disruptions in Sudan. Vapor and Modern Oral revenue each grew strongly, fueled by geographic expansion and ongoing progress in emerging markets. HP revenue took a hit from our price repositioning in Japan last year. Smokeless products now account for 18% of regional revenue in the markets where we operate, and adjusted profit from operations climbed 4%, backed by strong pricing and continued efficiency gains. Now, coming back to our group performance. Our operating margin stayed flat as we successfully offset high single-figure inflation and a transactional FX headwind of nearly 2%, helped by improving New Category profitability and continued efficiency gains. Inflation was mainly tied to leaf, which we expect to ease in the second half. Moving now to EPS, we delivered organic constant currency adjusted diluted EPS growth of 1.3%. Our performance gained from lower net finance costs, tax, and share count, partly offset by our reduced share of ITC profits. Our underlying tax rate came in at 24.4%, and we still expect a rate of around 25% for the full year with existing tax rates.
Soraya Benchikh
executiveBAT generates a lot of cash. With 78% cash flow conversion in the first half, we're well on track for another year of cash conversion above 90%, thanks to our continuous improvement mindset and additional resource optimization. Because of the timing of leaf purchases and MSA payments, our cash flow is always weighted toward the second half. We now expect full-year gross CapEx of around GBP 600 million, below adjusted depreciation and amortization. That's above our previous guidance of GBP 550 million, as we expand production capacity in the fast-growing Modern Oral category. We're making good progress on deleverage and expect to be within our narrow target range of 2x-2.5x at year-end. We've seen some improvement in the interest rate environment, with lower rates and tightening credit spreads. That, together with the cash we received from the ITC asset sale, has resulted in lower than expected net finance costs. As a result, we now expect full-year net finance costs to be around GBP 1.7 billion, subject to both FX and interest rate volatility. As we continue our transformation journey, we're focused on the importance of disciplined capital allocation and strong shareholder returns. We're committed to a progressive dividend, and we're making good progress on deleverage.
Soraya Benchikh
executiveWe're dedicated to a sustainable share buyback, and in March we restarted one, beginning with GBP 700 million in 2024 and GBP 900 million next year, made possible by monetizing part of our ITC stake. Going forward, we're making targeted investment choices to drive our medium-term sustainable growth algorithm. As expected, continued macroeconomic pressures and investment in our commercial actions affected our first half performance. We're confident our second half will accelerate, and we remain on track to deliver low single-digit organic revenue and adjusted profit from operations growth, including a 2% transactional FX headwind for the full year. Extrapolating current spot rates, we expect currency translation to be a 4% headwind on full year adjusted profit from operations growth. Now, beyond 2024, we expect to progressively improve our delivery to 3%-5% organic revenue growth, and mid-single-digit adjusted profit from operations growth on an organic constant currency basis by 2026. And with that, I'll hand back to Tadeu. Thank you.
Tadeu Marroco
executiveThank you, Soraya. At this point I'd like to take a few moments to lay out the opportunity and the path forward for BAT, and to explain why we're confident about delivering an acceleration in second half performance. Four clear accelerators should drive our second half delivery: better U.S. performance, innovations across all three new categories, and double-digit revenue growth for the full year. On top of that, we are lapping a softer comparator in APMEA, and we expect AME to keep performing strongly. Consequently, we remain confident about delivering our guidance for 2024. Turning to the U.S. premium segment, a clear correlation is visible between consumer sentiment and premium segment volume trends. Macroeconomic and historical shocks have significantly affected consumer sentiment, and that, in turn, has driven an accelerated decline in premium volumes. Yet as consumer confidence levels improve over time, premium volume decline typically stabilizes, returning to a more normalized level. While the U.S. market keeps evolving, we believe this further supports our outlook for improving U.S. delivery over the medium term. A key feature of our industry in recent years has been the strength of the deep discount segment, as consumers looked to make their dollar stretch further.
Tadeu Marroco
executiveWe're beginning to observe that deep discount volume growth is slowing sharply, and market share has stayed roughly level from Q3 of last year onward. Meanwhile, the branded value segment has picked up volume share, and BAT has gained share within that segment, with Lucky Strike leading the way. Although our full year guidance does not incorporate any macroeconomic improvement, we think this early signal of recovery among low-end consumers might act as a tailwind over the medium term. I'd like to give you additional detail on the portfolio actions we've implemented, and explain why we're confident these will produce better performance going forward. On premium, we've put investment behind Newport soft-pack in key investment states, building a laddered portfolio, and that has helped Newport's share of the total premium segment recover. As a result, we've achieved a 30% reduction in smokers switching away from the Newport brand family, which has produced an 80% reduction in low-end growth across the 19 states where Newport soft-pack has been launched. Zooming out, we hold a balanced brand portfolio spanning every price point. Via our commercial initiatives, we've delivered steady value share gains both in premium with Natural American Spirit and in branded value with Lucky Strike.
Tadeu Marroco
executiveNatural American Spirit has a very loyal consumer base, and that helps its distinctive positioning in the super premium segment. Lucky Strike, which we relaunched three years ago, is still the fastest-growing cigarette brand in the market. One key part of our commercial investment has been widening the contracted distribution universe over the last 12 months, and we've reached 88% coverage. That has made our competitive position much stronger, because more of our retailer partners now get increased sales force support. In these newly contracted outlets, this has driven a 2.3 percentage points increase in volume share, with share gains across our brands. On top of that, it has led to a 1.6% decline in the deeper discount segment in these outlets. All in all, with these previously announced commercial initiatives now in place, we're confident our actions will drive a better second half performance in the U.S. and further strengthen our portfolio over the medium to long term. Turning to regulation, we keep advocating for more appropriate regulation and enforcement of new categories, especially in U.S. vapor. During the first half, we saw the FDA step up enforcement action, with increasing fines, import refusals, and seizures. Also, the U.S. Justice Department and FDA recently announced they're creating a task force designed to harness the enforcement capabilities of multiple federal agencies to combat illicit products.
Tadeu Marroco
executiveThat said, whether legal products succeed hinges on the FDA stepping up its efforts against illicit vapor. Along those lines, we keep pushing for a PMTA list to be published, since that would give every market participant clarity. I was glad that only last week the U.S. International Trade Commission said it will look into our patent infringement complaint targeting the makers, distributors, and retailers of single-use illicit products. On top of that, the ITC is still investigating our complaint regarding unfair imports of these illicit products. The pressure for enforcement is plainly mounting. Even so, far more action is needed if we want a meaningful impact over the medium term. When it comes to the states, vapor directory or enforcement legislation has passed in 13 states so far, which means that once implemented, 31% of the tracked vapor industry volume will fall under state directories. In Louisiana — the first state to put a vapor directory into effect with significant enforcement in October 2023 — we're beginning to see illicit product volume come down, and Vuse Alto is capturing most of the volume flowing back into the legal segment. Louisiana stands as a powerful blueprint for what can be achieved. Even so, it's worth noting that vapor directories and regulation vary materially in scope from state to state, and that far more must be done to make sure these regulations are effectively enforced.
Tadeu Marroco
executiveMoving on to heated products now. As Soraya mentioned, we're beginning to see a turnaround in glo's performance, and Hyper Pro is what's driving it. Since most of our launches are now in place from the first half, we're confident that we can build on this momentum for the remainder of the year. The step change in performance is clear, with volume share gains in key HP markets, Japan, Italy, and Poland. Our Pro device has a premium price positioning, and the launch of our upgraded consumables has enabled us to take price increase in key markets. Importantly, since December, our value share in these key markets is now growing faster than our volume share, reflecting the strength of our innovations and commercial actions. So what has driven this turnaround? I have been very transparent that we needed to do more to strengthen our HP performance, and this all begins with better products. Leveraging our consumer insights, glo Hyper Pro and consumables are resonating strongly with consumers across key attributes, such as brand equity and perception. This is also driving an increase in average daily consumption among glo consumers. These launches are the first step in our enhanced innovation pipeline for heated products, and are a significant driver in the progress we are making to improve glo's category contribution.
Tadeu Marroco
executiveWhen it comes to vapor, we've begun rolling out some exciting innovations, and we have significant launch plans lined up for the second half. Our newest single-use vapor, Vuse Go 2.0, delivers improved sensorials thanks to superior heating technology. Importantly, it's our first device featuring a removable battery, and that — along with a device lock — directly tackles key sustainability and safety concerns. We keep upgrading the rechargeables experience with our Vuse Go Reload device, which pairs with our improved Vuse; Vuse Go Reload offers the flexibility and convenience of single-use products in a rechargeable device. Also, earlier this month in the U.S., we entered the emerging zero-nicotine space by launching Sensa. Taking all of this together, we're confident these innovations can drive and improve Vuse performance in the second half. In Modern Oral, we're reinvigorating our U.S. portfolio. I'm delighted with how our refreshed Velo brand expression has performed in our New York pilot, which has pushed volume share up 7.2 percentage points to June versus pre-pilot levels, reaching 16.5%. Because of that success, earlier this year we began a national rollout of refreshed Velo. Drawing on our consumer insights, we continue to innovate, broadening our offering and appealing both to traditional oral consumers through Grizzly Modern Oral and internationally by enhancing our flavors range.
Tadeu Marroco
executiveSo as you can see, we’ve got exciting new innovations hitting the market in every New Category, and those will fuel our acceleration in the second half. It’s encouraging that our New Category launches, along with the commercial investments we made in the first half to strengthen our U.S. combustible portfolio, are gaining traction — and that, combined with the unwinding of U.S. wholesaler inventory movements, I’m confident will drive, and will drive, an acceleration in group performance during the second half. Because of that, we remain on track to deliver our full year guidance. To wrap up, 2024 is an investment year for BAT. We’re sharpening how we execute so we can navigate near-term market challenges and position the business for a stronger future. Throughout our transformation, we’ll keep rewarding shareholders, supported by consistent cash flows, disciplined, disciplined capital allocation, and strong shareholder returns. There’s more to do, but our focus on quality growth is building momentum, and I’m confident this is the right approach to make sure we deliver long-term growth and value creation. Thanks for listening. Victoria will now join us on stage for the question and answer session.
Victoria Buxton
executiveThanks, Tadeu, and good morning, all. If you're with us on the webcast, you can enter your questions right into the online question box, or if you're on the call, just press star one on your telephone keypad. Tadeu and Soraya will be very glad to take your questions, and at this point I'll turn things over to the conference call operator.
Operator
operatorThanks, and the first question we have today is from Rashad Kawan at Morgan Stanley. Go right ahead.
Rashad Kawan
analystHi there, good morning Victoria, Tadeu, and Soraya. Appreciate you taking my questions, and congratulations on the results. I've got a couple, both focused on the U.S., if you don't mind. Turning to the combustibles market: when I look at slide 21, where you set out the impacts on the market, and what you had across the full year, the main deterioration stems from higher elasticities. Would you say that's driven purely by increased poly usage, or is it simply lower volume as smokers reduce consumption, given the pricing backdrop and generally weak sentiment? I suppose what I'm asking is whether you've observed a meaningful shift in consumer elasticity in U.S. combustibles. My second question returns to Modern Oral, again in the U.S. Honestly, the acceleration we're seeing comes as a bit of a surprise, since you still don't have your clearly more superior European product in the U.S. Is this purely down to the brand refresh you've carried out, or are you gaining somewhat from shortages at one of your competitors? I'd welcome any additional color on what's happening with U.S. Modern Oral, I think. Thanks. Thanks once more.
Tadeu Marroco
executiveAlright, Rash. So regarding U.S. combustibles — we aren't really seeing any huge erosion when it comes to cigarette elasticity. What's hitting us, and the whole industry, is a mix of a really tough macro backdrop. Keep in mind we came out of pandemic times when there was a lot of support from the state and federal level going to consumers, and that got fully reversed, entirely pulled out, and meanwhile the consumer was slammed by very high inflation and very high interest rates too, which put mostly low-income consumers under serious financial strain. So that clearly has an effect and shows up in consumer sentiment. That's the reason we include the correlation in our presentation. Then the other obvious factor there is the spread of illegal single-use vapor products here in the U.S. That category keeps expanding even though the legal portion of it is actually shrinking right now. All of the growth more than offsets the decline on the legal side and flows into those illicit products, and that is adding more pressure. So those are the main drivers behind why we're seeing this high single-digit industry decline in the U.S.
Tadeu Marroco
executiveIt's worth pointing out that we're starting to see some early positive signals on the macroeconomic front. Inflation has been declining, wage inflation is catching up and closing the gap with overall inflation. Consumer sentiment has ticked up slightly as of late, and together with a possible Fed action to cut interest rates before the year is out, all of that could be favorable as we head toward 2025 and 2026. Now, your question on poly users is the right one, since ultimately we are seeing a more poly-user dynamic in the U.S. market. So keep in mind that prior to the pandemic, we tended to see a secular decline in the U.S. of roughly 4%-5%. My view is that this high end of the range will, once things settle on the macro side, turn into the low end of a new range, roughly 5%-7%. That, I'd say, is my best estimate going forward, once things begin to stabilize and we see at least a minimal level of enforcement against illegal products. Now, the Modern Oral question you're raising. I think most of what has driven the improvement in ours has to do with our new expression of the brand, because we've been piloting since Q3 of last year in New York, and we were already seeing some traction there before any kind of distribution issues with competitors showed up in the market.
Tadeu Marroco
executiveAnd clearly, that more recent case is likely contributing to some of the growth in our offer as well. But keep in mind that we had already grown in New York at the end of last year, and that is exactly why we chose to launch the national rollout in the first quarter of this year. And certainly, we have now also grown Grizzly in a new offer. It's early days, since we observed many Grizzly consumers actually shifting our interest toward these new emerging segments, and we are attempting to account for this through a very strong brand portfolio power, which is Grizzly in the U.S.
Rashad Kawan
analystI appreciate that.
Operator
operatorThanks. Next up, we have a question coming from Gaurav Jain at Barclays. Go ahead, please.
Gaurav Jain
analystGood morning. I have three questions, and the first one is for Soraya. If I look at your FX guidance, there's a 4% headwind, and given your presence in so many emerging markets, that has been a structural issue with BAT. It was an issue for a lot of other FMCG companies, and we're now hearing from several companies, including Philip Morris, Unilever, Coke, that they're targeting dollar EPS growth or a pound EPS growth. So is that something which BAT would also like to move to that, instead of just a constant currency EPS growth, actually try to have meaningful pound EPS growth?
Soraya Benchikh
executiveI'm sorry, but do we feel sure we can generate EPS growth excluding the FX effect? In other words, on a current currency basis.
Tadeu Marroco
executiveMm-hmm.
Soraya Benchikh
executiveAnd as we move ahead? Yeah.
Tadeu Marroco
executiveMm-hmm.
Soraya Benchikh
executiveSorry about that, Gaurav. I missed the tail end of what you asked. Let me make sure I have it right — is the question whether we feel confident about driving EPS growth on a constant-currency basis? Was that it? On current terms.
Gaurav Jain
analystLook, I think, you know, with BAT, it's clear that there's guidance indicating you're able to grow EPS on a constant currency basis.
Soraya Benchikh
executiveYeah.
Gaurav Jain
analystYet that hasn't happened. I mean, pushing pound EPS growth has been tough.
Soraya Benchikh
executiveYes.
Gaurav Jain
analystThe reason for that is FX has been a structural headwind, and some of your peers, Philip Morris included, are now talking about hard currency EPS growth. So what I'm trying to understand is whether that's something BAT should do as well? And perhaps, Tadeu, you could also weigh in on that.
Soraya Benchikh
executiveYes, Gaurav, I’m confident that we can drive EPS growth on the current terms. Would you like to add anything to that?
Tadeu Marroco
executiveSure. Gaurav, keep in mind that our figures reflect transactional FX, right? A number of the businesses you’re mentioning report at constant currency, and those figures actually leave out transaction effects — which makes the gap between constant and current even wider, to put it that way. So certainly, in years like the ones we’re dealing with now, when there are a lot of devaluations, especially across emerging markets, it’s hard to imagine fully offsetting all of that. But as Soraya said, over the medium term, on a current basis, we should be able to deliver that.
Soraya Benchikh
executiveYeah.
Gaurav Jain
analystCertainly. My second question concerns your NGP revenue and volume, and how those performed in 1Q. Heated tobacco volumes on an organic basis have declined, and they fell in Japan too; you did considerable price repositioning in 2H23, and your e-cigarette business has declined as well. So does it make sense to steer a greater share of investment toward e-cigarettes and away from heated tobacco? If not, both segments are declining.
Tadeu Marroco
executiveAlright, so in AME, the situation has been affected — and we mention this in our presentation — by some inventory movements we carried out at the close of last year to get ready for the flavor ban on heated tobacco products. Since in certain markets we need to begin selling Vuse, which is our non-tobacco-flavor product. And once you adjust for that, AME, I believe delivered revenue of 2% and volume of 7%; volume would actually be in double digits on an adjusted basis. So honestly, I'm quite pleased with the progress we're achieving. Take a market like Poland — we hold roughly 34% share of the category there — and in a tough market such as Italy, we're beginning to see some improvements. The same is happening in Japan. Keep in mind that last year — and I was extremely clear and transparent on this — when I arrived as CFO, I said we lacked a genuinely competitive THP product, and we've also succeeded in putting in place a product that is far superior. You've seen some of the statistics I presented today. And when you factor in that penetration of these devices averages 15%, all those improvements you saw on my slide regarding everyday consumption, conversion, and retention will only keep growing from now through the end of the year.
Tadeu Marroco
executiveAnd don't forget the additional platforms where we're currently developing our pipeline. So I'd say the answer is yes, we ought to be putting money in. I believe we're up against a tough comparison period, largely due to insufficient competitiveness and. Yet I'm fairly confident that we've begun to reverse our competitive standing in THP.
Gaurav Jain
analystThanks. And for my final question, on e-cigarettes — obviously it's great to hear you've gotten the PMTA. Could you remind us where your PMTA pipeline stands now for e-cigarettes in the U.S.? And clearly Vuse is performing quite well internationally, so how should we think about upcoming PMTAs?
Tadeu Marroco
executiveOn the PMTAs—so what's been cleared so far is essentially the tobacco-flavored Alto, Vuse Ciro, and Solo, which, as you're aware, represents the biggest set of combined PMTAs the U.S. has received up to now. The menthol version, as you know, is something we're contesting, and the reason we keep selling it is our belief that we hold the data the FDA needs in order to take into account. So the stay came through, and we're hopeful it can be reviewed down the road. Just last month we submitted the PMTA for our age-gated device. That one covers not only flavor but a couple of fruit flavors too, plus menthol in the mix. Of the PMTAs we're now waiting on, I'd have to say this is the most pressing. Given that it's age-verified—with age verification technology—we're very hopeful the FDA can, as they've stated, move quickly to approve this PMTA. Because this is likely to be one tool they'll be weighing as they, they try to bring back, you know, flavors that are so critical to, to, to shifting adult smokers off cigarettes and toward vapor in a responsible way.
Gaurav Jain
analystI really appreciate it.
Operator
operatorThanks. Just a quick note that this is star one for your phone questions today. Our next question comes from Richard Felton at Goldman Sachs. Go ahead, please.
Richard Felton
analystThanks. Morning to everyone. I have two questions, if I may. First one concerns vapor in markets outside the U.S., where I believe volumes fell nearly 10% during H1. Could you give us any color or specifics on what drove that decline, and tell us whether those factors are one-off in nature or whether we should be watching for more structural headwinds? My second question is also about new categories. I would really like to get a sense of how you are weighing revenue growth against profitability improvement going forward. Because stepping back and reflecting on how you performed across the last few years, revenue guidance was missed, yet profitability came in much stronger than the guidance you had given before. Looking ahead, how are you thinking about running the P&L for that portion of the business, and how do you strike the balance between putting investment into additional growth while also lifting margin? Thank you.
Tadeu Marroco
executiveAlright, I'll take the second question. About your vapor question — outside the U.S., it's largely a Canada effect. Essentially, Quebec brought in new legislation capping the amount at 2 ml and prohibiting every flavor except tobacco, with no enforcement at all. So the very next day, what we witnessed was a flood of illegal products reappearing — large tanks loaded with flavors — and obviously there's no level playing field, and that's the outcome you're seeing in Canada. In a sense, it's a one-off until regulators wake up and either enforce properly or revisit that regulatory piece. That's exactly why the second pillar of our strategy centers on tobacco harm reduction — it's about having evidence, scientific evidence, points for discussion with key stakeholders, regulators and policymakers, so we can prevent this kind of highly misleading regulation from being introduced without proper enforcement, you know? So if you set Canada aside, AME actually grew 15% in revenue as a region, and that's with no contribution from any of those products I showed in my slides.
Tadeu Marroco
executiveRegarding Vuse, glo, glo 2.0, and Vuse Go Reload — all of these are arriving in stores now in May, so there hasn't been any time yet when it comes to the shares or the performance you observed in the results, this early today. Other markets that have us quite enthusiastic include places such as New Zealand, which has now shifted toward a more well-rounded regulatory environment and lets us compete properly there, and we're picking up a lot of traction with our offerings in New Zealand. Korea is quite exciting as well. Within a very short period of time we're already market leaders in Korea, and we also see prospects in markets such as Indonesia. Broadly speaking, in summary, it's a consequence of the regulatory impact in Canada.
Soraya Benchikh
executiveI'll take that second question. When it comes to striking a balance between growing revenue and expanding margins, as you may remember, I said our real priority is balancing growth on the top line with growth on the bottom line, and we will… What we're really aiming to do is keep investing, but focus those investments more on all the categories showing momentum, and also on the places where there's greater value, whether that's in categories or in geographies. So by targeting our investment, what you'll see is that we'll keep balancing both the top and the bottom line, and the proof of that is in the first half, where we showed category contribution had gone up by more than — I believe it was roughly GBP 167 million. And that has widened category contribution by 10 percentage points. So as we move forward and into the full year, our targeted investments will continue, and as Tadeu said, we are very much weighted toward the second half when it comes to innovations reaching the market. So we'll have a fair amount of investment in the second half, but you will keep seeing our category contribution rise year on year. And targeting our investments and building up our margins will be a really big priority for us going forward.
Richard Felton
analystThanks, that’s clear.
Operator
operatorThanks. Our next question comes from Faham Baig at UBS. Go ahead, please.
Faham Baig
analystMorning, everyone. I have a couple of questions too, if I may. First, returning to the higher vaping levels you're observing: a competitor said, I believe, that conversion rates among consumers for vapor are below those for heated tobacco. I'd like your view on the conversion rates you see across those two categories, and then on how you see each category's prospects more broadly. My second question returns to U.S. vapor. You've quantified in the past the overall category's growth and what it does to cigarette volumes — could you remind us of that? By what point do you expect stepped-up FDA enforcement could start to weigh on how these disposable products develop? And, if you can address it, you flagged some benefits in Louisiana. What about Oklahoma and Alabama, the other two states that have set up registries? Perhaps what you're seeing there would be useful too.
Tadeu Marroco
executiveRight, okay. So regarding poly users — I believe we shared some statistics last year at a conference we took part in, comparing vapor with HP. And between those two categories, we aren't seeing any major material shift when it comes to conversion. So we don't accept that comment that one has a far stronger conversion rate than the other to begin with. And it's worth remembering that vapor already accounts for 65% of consumption in this new non-combustibles space, and it's growing quickly too. That's different from THP, which, if anything, is slowing down as a category — largely driven by the poly user phenomenon. And that's not only because of vapor, but also because of very accelerated growth now in Modern Oral. On U.S. vapor, what we cited earlier is a figure of roughly 2% decline that's tied directly to the spread of those illegal products. If anything, we haven't observed any kind of slowdown in growth. I'm not in a position to claim that all those headlines you've been reading have had a positive reflection in the market, because we don't see that being the case. In fact, the slight share loss we had in vapor was precisely due to those illegal products in the trade channels, for the most part.
Tadeu Marroco
executiveThey’re still growing. There’s — it’s really hard to say when we’ll actually see enforcement, because we were looking for the FDA to wrap up the PMTA of vapor process by the end of June. Well, at first it was the end of December last year, and now it’s been pushed to the end of June. So we still haven’t seen it. That’s why in my presentation I made a reference to the FDA needing to truly finish this process and be able to state clearly in public what’s allowed and what isn’t, since that can help enforcement tremendously, at least on the tracked channels, where we keep seeing illegal vapors’ participation grow. Now, Louisiana is state-of-the-art when it comes to regulation. So we’re seeing big progress in reducing illegal products there, and Vuse has benefited substantially as a major beneficiary with a reduction in the illegal products. And the other two aren’t at the same level, because as I mentioned, they don’t have the same type of regulations. But it’s a good starting point, because what you can do is improve the regulation as soon as you start that.
Tadeu Marroco
executiveIn the remaining two states, there’s been some decrease, though it doesn’t match what happened in Louisiana, since that state’s approach is more complete — they’ve just, you know, also brought in an excise. They rely on it to fund proper enforcement within the legislation, and they have a... if you look at the specifics of the legislation, it’s much more, I’d say, comprehensive compared with those other two states.
Faham Baig
analystAppreciate it.
Operator
operatorThanks. Our next question comes from Damian McNeela at Deutsche Bank. Go right ahead.
Damian McNeela
analystGood morning, everyone. I have two questions, please. First, regarding the U.S. Combustibles business, you said contracted coverage has gone from 82% to 88%. I'm wondering what a reasonable coverage level would be for the U.S. and how long it would take you to reach it. And then, more broadly, how pleased are you with the progress made in the commercial organization in the U.S., and is there anything more that can be done to drive an improvement in performance there? And the second question is just on—Soraya mentioned an incremental GBP 50 million going into Modern Oral capacity. I'm wondering if you could indicate how much headroom those investments give you going forward, please.
Tadeu Marroco
executiveRight, yes. Regarding coverage, we always evaluate the investment and what return we get from those retailers. We've reached a point where we feel very satisfied with where we stand. That's the reason I mentioned that most of the commercial plans have already been concluded. We did that on the back of adding 150 new reps to our sales force, so we expanded the sales force in order to accomplish that. We're also investing heavily, even more, when it comes to data analytics, revenue growth management, and systems in general, and those form part of the commercial plans along with laddering and price adjustments, and so on. So we're pretty much there regarding what we need to do. You saw some of the improvements we've been achieving recently when it comes to volume share, value share, and the premium segment. And so I think we're in a very strong position now to benefit when the market starts to improve at the macroeconomic level and from the enforcement levels on illicit products. But it's important to note that nicotine consumption in the U.S.
Tadeu Marroco
executiveIt's still fairly steady. The issue is that growth is happening in areas where we currently can't take part. As I've said before, these illicit vapor markets make up over 60% of the vapor category, which works out to roughly GBP 60 billion in revenue that becomes available the moment there's even minimal enforcement in that space. Add to that the rise of Modern Oral, a category where we are now—even though our winning products aren't there yet in the U.S., since they're awaiting PMTA approval, as you know—still managing to make some headway with the product we currently have following certain tweaks we've made more recently. Modern Oral is expanding in every market, and I think you likely picked up on our remark that 25% of those markets are now outside, or are located in places where the industry had no oral tradition previously. That's translating into enormous growth, and BAT, through our product Velo, is capturing over 7% of that growth occurring in ME outside the U.S.
Tadeu Marroco
executiveWe’re in a genuinely strong position: we have a brand consumers truly love, it’s being activated very effectively, and hopefully that will be helped along by some of the improvements we’re making in the U.S. And above all, once we’re really able to have this product available in the U.S., that will be a fantastic opportunity for the group going forward. I’ll hand it over to Soraya to respond on the CapEx.
Soraya Benchikh
executiveOn CapEx, sure — we're continually upgrading. As you can see, Modern Oral's trajectory has been quite striking. In the first half by itself, we grew 47%. So we're constantly seeking to put more money in, to boost capacity, whether that's for the U.S. or in Europe. That's why we've raised our CapEx figure for this year from GBP 550 million to GBP 600 million.
Damian McNeela
analystAlright, thanks.
Operator
operatorThanks. So with that, I’d like to give the call back to you, Victoria, for any questions that come in through the webcast.
Victoria Buxton
executiveThanks. We’ve got a few web questions. Soraya, this one is likely for you. What portion of the raw material increase came from leaf costs, and what portion came from FX? Also, how much do you expect that to unwind over the next six months and over the next year?
Soraya Benchikh
executiveSure — we saw a pretty meaningful rise in leaf costs. Raw materials, I believe, were up about 9%-10%, while leaf was up roughly 14%. That’s easing a lot in the second half, and we expect the bulk of it to reverse by next year. Still, it’s been a weight on the overall operating margin, or on gross margin for combustibles, which we hope turns into a tailwind for us next year.
Victoria Buxton
executiveMoving on to the next question: will the FII GLO payments have any effect on our buyback plans for next year?
Soraya Benchikh
executiveSo the FII GLO payments — GBP 0.8 billion across 4 years — we've known those yearly amounts well, and they were fully factored into our forecast when we actually announced the buyback stemming from the sale of our ITC stake. We committed GBP 700 million, which we began in March, and we'll carry out the buyback of the remaining GBP 900 million to complete the GBP 1.6 billion from that ITC stake sale.
Victoria Buxton
executiveWell, our apologies — it seems there aren't any further questions coming in from the web. If you weren't able to get your question in, please feel free to reach out to the IR team, and we'd be very happy to assist. So with that, I'll turn things back over to Tadeu for some closing remarks.
Tadeu Marroco
executiveAll right. Thanks for tuning in today and for your questions. I hope it's clear to all of you that this year represents a pivotal point in the journey of transformation we're on. I have confidence that the investment target we've chosen is the right one, and that the decisions we're taking are the right ones to deliver growth over the long term and create value. I'm looking forward to keeping you posted on how we're progressing, and I hope to see plenty of you at our Capital Markets Day, which takes place at our innovation center in Southampton on the 16th of October. There you'll get the chance to see for yourselves how our teams are concentrating on lowering the health impact of what we do and on enabling BAT to deliver sustainable value over the long term for all our stakeholders. Many thanks.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete British American Tobacco p.l.c. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to British American Tobacco p.l.c. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in British American Tobacco p.l.c. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.